Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
53 hedge funds and large institutions have $118M invested in Eiger BioPharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 8 closing their positions.
70% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 10
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
6% more funds holding
Funds holding: 50 → 53 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $120M → $118M (-$2.51M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$3.83M |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$589K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$570K |
| 4 |
Renaissance Technologies
New York
|
+$554K |
| 5 |
AG
Algert Global
San Francisco,
California
|
+$515K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
GMT Capital
Atlanta,
Georgia
|
-$3.46M |
| 2 |
HCM
Highbridge Capital Management
New York
|
-$1.72M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$1.11M |
| 4 |
UC
Unterberg Capital
New York
|
-$976K |
| 5 |
Millennium Management
New York
|
-$871K |
EIGR Hedge Fund Activity: Q3 2018 in Review
53 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q3 2018, worth a combined $118M — down 2.1% from $120M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new EIGR positions and 8 closed out — a net gain of 3 holders — while 17 added to existing stakes and 10 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $3.83M. The largest seller was GMT Capital, exiting entirely with an estimated $3.46M sold.
- 53 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q3 2018, up from 50 in Q2 2018.
- Funds reported $118M of Eiger BioPharmaceuticals, Inc. stock for Q3 2018, down 2.1% quarter-over-quarter.
- 11 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q3 2018 and 8 closed out, a net change of +3 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q3 2018 was 683 Capital Management, an estimated $3.83M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q3 2018 was GMT Capital, an estimated $3.46M sold.
Based on aggregated 13F filings for Q3 2018.